undamentalytics Newsletter
Sign in

Bioaffinity Technologies, Inc. (BIAF) stock

Add to watchlist

Add holding +

NASDAQ: BIAF Nasdaq Health Care Equipment Next results ~November 13, 2026

C Fundamentals grade

Bioaffinity Technologies, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.8

Price-to-sales vs peers

Base case. Range ~$0.8–$4.3. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Bioaffinity Technologies, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds12 adding, 5 cuttingOf 1 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Bioaffinity Technologies files

Where Bioaffinity Technologies stands after its latest Filing

Revenue for the twelve months was $6m, down 23.2% on a year earlier, a smaller fall than the 35.8% decline a quarter earlier. That puts it 99 of 103 for growth among the health care equipment companies we cover. Free-cash-flow margin fell to -195.9% from -100.9% a year earlier. Operating margin narrowed to -209.8% from -131.0%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 4 of our 6 financial-health checks. Our price-to-sales vs peers value is $1.09 a share, against a share price of $3.25.

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 13, 2026 (estimated)

Bioaffinity Technologies, Inc.'s trailing-twelve-month revenue fell 23.2% year on year, with a free-cash-flow margin of -195.9%. Where it stands out: change in growth rate of +12.6pp ranks 12 of 129 health care equipment companies we cover. Where it lags: revenue growth of -23.2% ranks 123 of 129 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 49.2% while net income fell 29.9%: a 19pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 13 November; the share price can move sharply on the day.
  • Revenue shrinking. Revenue fell 23.2% over the last 12 months.
  • Loss-making. Operating margin is -209.8%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 78.8 points on a year ago.
  • Burning cash. Free cash flow was -195.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 15.8% of revenue, against a median of 6.1% for health care equipment companies we cover: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
-$71.10 against an average estimate of -$40.50: missed by 75.6%
Revenue
$2m, up 19.0% on a year earlier
Share reaction
-7.5% in the first session after the results on August 7, 2026, against +0.6% for the S&P 500

Bioaffinity Technologies' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.7%
  • 1 week+5.7%
  • 1 month-50.6%
  • This year-83.1%
  • 1 year-91.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$5.9M
Operating margin
-209.8%
Net margin
-257.3%

Growth

Revenue growth
−23.2%
Change in growth rate
+12.6 pts

Cash

Free cash flow (TTM)
-$11.6M
FCF margin
-195.9%
Stock pay % of revenue
15.8%

Earnings

Last results
August 7, 2026
Next results (est.)
November 13, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Agreement
  5. Announcement
  6. Announcement
  7. Announcement
  8. Announcement
  9. Announcement
  10. Announcement
  11. Announcement
  12. Announcement
  13. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bioaffinity Technologies, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Bioaffinity Technologies, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 7.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.67 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.8 ~$1.0–$4.3 Included, half weight
Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.8 ~$0.8–$4.3 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Bioaffinity Technologies, Inc. with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025
Share price$720.00$661.95$409.50$17.70
Market value$216m$193m$166m$30m
+ Net debt (− = net cash)−$11m−$3m−$913442−$6m
Enterprise value$205m$190m$165m$24m
Multiples
Price / sales 31.3x24.4x17.7x4.9x
Price / earnings ————
Price / free cash flow ————
EV / EBITDA ————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Bioaffinity Technologies, Inc.: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2025 −$40.50 −$71.10 −75.6%
Jun 2025 −$45.00 −$76.50 −70.0%
Mar 2025 −$72.00 −$72.00 0.0%
Dec 2024 −$63.00 −$94.50 −50.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 7, 2026

No numeric guidance in Bioaffinity Technologies, Inc.'s latest earnings release (filed August 7, 2026). Some companies give their outlook only on the earnings call.

Positioning

Short interest
5.2%
of tradable shares
Days to cover
0.02
at average volume
Short interest, 1 month
−6%
to October 15, 2026
Held by institutions
5%
of shares
Held by insiders
0.8%
of shares
Employees
57
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
BIAF−8%−38%−96%−83%
Industry peers (median)−9%−19%−16%−13%
S&P 500+26%+25%+18%+11%
Months that ended higher
BIAF42%42%25%27%
S&P 50067%75%75%46%
Largest fall from a high during the year
BIAF−68%−71%−96%−96%
S&P 500−10%−8%−19%−9%

Worst fall since September 1, 2022: 100% from September 1, 2022 to October 23, 2026. Getting back needed a 133293% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.80 – $71.10
From 52-week high
−95.8%
vs 50-day average
−50.9%
vs 200-day average
−84.4%
Volatility (1 year)
207%
Beta vs S&P 500
2.56

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±43.0%
After a week
6 up, 6 down
typical move ±41.4%
After a month
8 up, 4 down
typical move ±37.1%
Results releasedNext dayS&P 500 next day5 days21 days
August 7, 2026 −7.5% +0.6% −24.2% +12.3%
May 8, 2026 −7.1% +1.1% −11.3% −28.8%
March 13, 2026 +78.5% +0.4% +155.1% +162.6%
November 14, 2025 −16.0% −0.9% −21.8% −26.6%
August 14, 2025 −16.8% −0.2% −11.1% +25.0%
May 15, 2025 −5.8% +1.1% +22.2% +16.4%
March 31, 2025 +316.0% +1.0% +167.2% +79.4%
November 14, 2024 +1.6% −1.9% −4.3% −31.7%
July 9, 2024 +5.5% +1.1% +2.5% −27.4%
May 16, 2024 +20.2% −0.1% +30.9% +4.3%
April 1, 2024 +5.0% −0.8% +31.2% +21.3%
March 5, 2024 −36.2% −0.5% −14.5% +9.8%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Bioaffinity Technologies, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Bioaffinity Technologies, Inc.
$4M $6M $8M $10M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $9M Revenue (TTM), FY23 Q4: $4.4M Revenue (TTM), FY24 Q1: $5M Revenue (TTM), FY24 Q2: $7.4M Revenue (TTM), FY24 Q3: $9.4M Revenue (TTM), FY24 Q4: $9.4M Revenue (TTM), FY25 Q1: $8.8M Revenue (TTM), FY25 Q2: $7.7M Revenue (TTM), FY25 Q3: $6.8M Revenue (TTM), FY25 Q4: $6.2M Revenue (TTM), FY26 Q1: $5.7M Revenue (TTM), FY26 Q2: $5.9M $5.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $9M
FY23 Q4 $4.4M
FY24 Q1 $5M
FY24 Q2 $7.4M
FY24 Q3 $9.4M
FY24 Q4 $9.4M
FY25 Q1 $8.8M
FY25 Q2 $7.7M
FY25 Q3 $6.8M
FY25 Q4 $6.2M
FY26 Q1 $5.7M
FY26 Q2 $5.9M
Revenue growth, TTM YoY Bioaffinity Technologies, Inc.
-50% 0% 50% 100% 150% FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q2 Revenue growth, TTM YoY, FY24 Q1: -42.7% Revenue growth, TTM YoY, FY24 Q2: -15.6% Revenue growth, TTM YoY, FY24 Q3: 4.3% Revenue growth, TTM YoY, FY24 Q4: 113.4% Revenue growth, TTM YoY, FY25 Q1: 76.6% Revenue growth, TTM YoY, FY25 Q2: 4.3% Revenue growth, TTM YoY, FY25 Q3: -28.0% Revenue growth, TTM YoY, FY25 Q4: -34.2% Revenue growth, TTM YoY, FY26 Q1: -35.8% Revenue growth, TTM YoY, FY26 Q2: -23.2% -23.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 -42.7%
FY24 Q2 -15.6%
FY24 Q3 4.3%
FY24 Q4 113.4%
FY25 Q1 76.6%
FY25 Q2 4.3%
FY25 Q3 -28.0%
FY25 Q4 -34.2%
FY26 Q1 -35.8%
FY26 Q2 -23.2%
Operating margin (TTM) Bioaffinity Technologies, Inc.
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -80.4% Operating margin (TTM), FY23 Q4: -181.7% Operating margin (TTM), FY24 Q1: -167.6% Operating margin (TTM), FY24 Q2: -117.7% Operating margin (TTM), FY24 Q3: -88.7% Operating margin (TTM), FY24 Q4: -95.6% Operating margin (TTM), FY25 Q1: -109.4% Operating margin (TTM), FY25 Q2: -131.0% Operating margin (TTM), FY25 Q3: -153.2% Operating margin (TTM), FY25 Q4: -171.6% Operating margin (TTM), FY26 Q1: -204.3% Operating margin (TTM), FY26 Q2: -209.8% -209.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -80.4%
FY23 Q4 -181.7%
FY24 Q1 -167.6%
FY24 Q2 -117.7%
FY24 Q3 -88.7%
FY24 Q4 -95.6%
FY25 Q1 -109.4%
FY25 Q2 -131.0%
FY25 Q3 -153.2%
FY25 Q4 -171.6%
FY26 Q1 -204.3%
FY26 Q2 -209.8%
FCF margin (TTM) Bioaffinity Technologies, Inc.
-200% -150% -100% -50% 0% FY23 Q4 FY24 Q2 FY24 Q4 FY25 Q2 FY25 Q4 FY26 Q2 FCF margin (TTM), FY23 Q4: -138.2% FCF margin (TTM), FY24 Q1: -138.1% FCF margin (TTM), FY24 Q2: -96.2% FCF margin (TTM), FY24 Q3: -77.2% FCF margin (TTM), FY24 Q4: -78.4% FCF margin (TTM), FY25 Q1: -75.5% FCF margin (TTM), FY25 Q2: -100.9% FCF margin (TTM), FY25 Q3: -125.5% FCF margin (TTM), FY25 Q4: -152.4% FCF margin (TTM), FY26 Q1: -193.1% FCF margin (TTM), FY26 Q2: -195.9% -195.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -138.2%
FY24 Q1 -138.1%
FY24 Q2 -96.2%
FY24 Q3 -77.2%
FY24 Q4 -78.4%
FY25 Q1 -75.5%
FY25 Q2 -100.9%
FY25 Q3 -125.5%
FY25 Q4 -152.4%
FY26 Q1 -193.1%
FY26 Q2 -195.9%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 7 8 9 6 6
Gross profit 0 — — — —
EBITDA −4 −8 −8 −10 −12
Operating income −4 −8 −9 −11 −12
Net income −8 −8 −9 −15 −15
Diluted EPS −$27.15 −$0.91 −$22.50 −$8.66 —
Growth (year on year)
Revenue — +14.5% +18.5% −34.2% −23.2%
Margins
Gross margin 0.1% — — — —
EBITDA margin −58.0% −97.8% −89.2% −163.4% −202.8%
Operating margin −58.1% −100.9% −95.6% −171.6% −209.8%
Net margin −118.2% −100.5% −96.6% −242.0% −257.3%
Free-cash-flow margin −62.2% −76.7% −78.4% −152.4% −195.9%
Cash flow
Cash from operations −4 −6 −7 −9 −11
Capital spending 0 0 0 0 0
Free cash flow −4 −6 −7 −9 −12
Stock-based pay 0 1 1 1 1
Free cash flow after stock pay −5 −7 −8 −10 −12
Balance sheet
Cash 11 3 1 6 2
Total debt 0 0 0 0 0
Net debt (negative = net cash) −11 −3 −1 −6 −2
Diluted shares — — — 2m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

4 of 6 checks passed · June 30, 2026
What it owns · $8m
Short-term assets $4mLonger-term assets $4m
What it owes, and who funded it · $8m
Short-term liabilities $3mLonger-term liabilities $1mShareholders' equity $4m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $1m of longer-dated liabilities.
  • More cash than debt $2m of cash against $36,465 of debt.
  • Debt below 40% of shareholders' equity Debt is 1% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$11m of operating cash flow against $36,465 of debt.
  • Operating profit covers interest at least five times over Operating income of −$12m against $44,837 of interest.

From Bioaffinity Technologies, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
24.0%
of revenue
Sales & admin spending
192.3%
of revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated BIAF LUCD NRXS MCTA IVF XAIR Median
Revenue, last 12 months $6m $5m $5m $5m $8m $8m $99m
Revenue growth, last 12 months −23.2% 24.9% 65.2% −22.7% 13.8% 60.7% 9.2%
Revenue growth, 3-year average −12.2% 90.1% 25.6% — 85.6% 122.7% 13.5%
Revenue growth, latest quarter 19.0% 26.7% 115.7% — 16.7% 0.5% 10.2%
Gross margin 2.7% 2.1% 85.6% 99.3% 53.6% 4.2% 61.2%
Operating margin −209.8% −930.9% −144.5% −0.6% −78.7% −364.8% −8.5%
Operating margin, 3-year average −152.9% <−999% −249.7% — −97.0% <−999% −17.9%
Net margin −257.3% −959.8% −144.4% −0.5% −92.3% −435.7% −12.0%
Cash from operations / revenue −194.3% −860.8% −105.7% −25.3% −63.3% −241.5% −1.9%
Free-cash-flow margin −195.9% −876.8% −105.7% −32.4% −63.3% −255.0% −3.9%
Free-cash-flow margin, 3-year average −131.0% <−999% −224.0% — −77.4% <−999% −7.0%
Stock pay / revenue 15.8% 101.4% 9.2% — 64.3% 61.7% 6.1%
Change in share count — 103.6% 43.8% 5.3% 26.6% −99.0% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -23.2% 9.1% 123 of 129
Change in growth rate Growth +12.6pp -0.6pp 12 of 129
Operating margin Profitability -209.8% -8.3% 110 of 132
Net margin Profitability -257.3% -12.0% 112 of 133
Free-cash-flow margin Cash generation -195.9% -3.4% 109 of 128
Stock pay as % of revenue Cash generation 15.8% 6.1% 91 of 123
Long-term debt as % of assets Balance sheet 0.5% 24.2% 10 of 87

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Laboratory Services $6.2M 99.9% ▼ 34.1%
Health Care Patient Service $5M 80.7% ▼ 39.2%
Histology Service Fees $1.1M 18.1% ▲ 1.2%
Medical Director Fees $68,268 1.1% ▲ 2.5%
Other Revenues $4,860 0.1% ▼ 34.1%
Department of Defense Observational Studies $577 0.0% ▼ 93.3%
Diagnostic Research and Development $577 0.0% ▼ 93.3%

From Bioaffinity Technologies, Inc.'s 10-K filed March 16, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$609,025
Institutions reporting
17
Shares held vs prior quarter
▲ 210.0%
Positions opened / closed
8 / 4

Top buyers and sellers, Q2 2026: 12 institutions bought and 5 sold ; the biggest buyer was Sabby Management, LLC (+366K shares) and the biggest seller Schonfeld Strategic Advisors LLC (−24K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Sabby Management, LLC $296,905 366K 48.8% New
Blackrock, Inc. $80,207 99K 13.2% New
Vanguard Capital Management LLC $45,101 56K 7.4% 0.0%
Geode Capital Management, LLC $41,384 51K 6.8% ▲ 5.5%
Vanguard Fiduciary Trust Co $25,230 31K 4.1% 0.0%
Susquehanna International Group, LLP $21,818 27K 3.6% New
Jane Street Group, LLC $21,748 27K 3.6% New
State Street Corp $19,558 24K 3.2% ▲ 67.4%
HRT Financial LP $16,000 21K 2.6% New
Northern Trust Corp $13,599 17K 2.2% ▲ 31.6%
Virtu Financial LLC $9,000 11K 1.5% New
Allworth Financial LP $8,120 10K 1.3% New

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bioaffinity Technologies, Inc.'s complete shareholder register. Values are as reported by the filers ; 2 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 13, 2026 estimated from the company's past filing pattern, not announced

  • August 7, 2026
  • May 8, 2026
  • March 13, 2026
  • November 14, 2025
  • August 14, 2025
  • May 15, 2025

Recent SEC filings

Data status

When each part of this page on Bioaffinity Technologies, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bioaffinity Technologies, Inc. in brief

What does Bioaffinity Technologies, Inc. do?
Bioaffinity Technologies, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Bioaffinity Technologies, Inc.'s stock ticker?
Bioaffinity Technologies, Inc. trades under the ticker BIAF on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Bioaffinity Technologies, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Bioaffinity Technologies, Inc. reported revenue of $5.9M, 23.2% lower than a year earlier, according to its SEC filings.
What is Bioaffinity Technologies, Inc.'s free cash flow?
Bioaffinity Technologies, Inc.'s free-cash-flow margin is -195.9% of revenue over the trailing twelve months, ranking 109 of the 128 health care equipment companies we cover.
Who are Bioaffinity Technologies, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Sabby Management, LLC, Blackrock, Inc. and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Bioaffinity Technologies, Inc.'s market cap?
On December 31, 2025, Bioaffinity Technologies, Inc.'s market capitalisation was about $30.5M and net debt of -$6.3M. Market figures come from third-party market data and may be delayed.
How much debt does Bioaffinity Technologies, Inc. have?
Bioaffinity Technologies, Inc.'s debt-to-equity ratio is 1.0%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Bioaffinity Technologies, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Bioaffinity Technologies, Inc. are Lucid Diagnostics Inc., Neuraxis, Inc, Charming Medical Ltd, Invo Fertility, Inc. and Beyond Air, Inc. The side-by-side comparison below sets their revenue, margins and growth against Bioaffinity Technologies, Inc.'s.
When is Bioaffinity Technologies, Inc.'s next earnings date?
Around November 13, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Bioaffinity Technologies, Inc. announces its own schedule.